L&G Pharma Breakthrough UCITS ETF (CH:BIOT) Price & Chart

Morgan Stanley analyst Sean Laaman raised the firm’s price target on BeOne Medicines (ONC) to $476 from $465 and keeps an Overweight rating on the shares. The firm adjusted estimates

H.C. Wainwright raised the firm’s price target on Basilea Pharmaceutica (BPMUF) to CHF 120 from CHF 110 and keeps a Buy rating on the shares. The firm cites the company’s

Biogen Inc. ($BIIB) announced an update on their ongoing clinical study. Study Overview: Biogen’s official study title is “An Observational Study Utilising Data From EU National MS Registries to Estimate

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by

WSW, NY, November 11th, 2026, FinanceWire A reported offer for the established MC4R franchise and fresh funding for Lilly-backed Superluminal point to growing interest in the brain’s hunger pathway. Palatin

Barclays raised the firm’s price target on Xeris Biopharma (XERS) to $18 from $14 and keeps an Overweight rating on the shares. The company’s “impressive” Q3 was driven by Recorlev,

Barclays analyst Glen Santangelo raised the firm’s price target on Ligand (LGND) to $350 from $345 and keeps an Overweight rating on the shares. The share setup post the Q3

Needham raised the firm’s price target on Liquidia (LQDA) to $66 from $58 and keeps a Buy rating on the shares. The company’s Q3 update “paints a more positive picture”

BTIG analyst Julian Harrison raised the firm’s price target on Liquidia (LQDA) to $87 from $70 and keeps a Buy rating on the shares. Q3 results and October commercial metrics